Results 151 to 160 of about 30,963 (261)

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Risk factors influencing the treatment outcome in diabetic macular oedema

Indian Journal of Ophthalmology, 1996
A multivariate analysis was done on 96 eyes to evaluate the effect of various risk factors on the final visual outcome after laser photocoagulation for clinically significant macular oedema (CSME) in diabetic retinopathy.
Gupta Amod, Gupta Vishali, Dogra M, Pandav S   +3 more
doaj  

Cost‐utility of once‐weekly insulin icodec versus once‐daily basal insulins for type 2 diabetes in China

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 3872-3882, May 2026.
Abstract Objective To comprehensively assess the cost‐utility of icodec, the first once‐weekly basal insulin, at 700 and 1050 U formulations compared with once‐daily basal insulin analogues in Chinese adults with type 2 diabetes within reimbursement context.
Xichen Tong, Chang Xing, Lei Zhang, Luying Zhang   +3 more
wiley   +1 more source

STUDY OF CHANGE IN MACULAR VOLUME WITH UNCONTROLLED HBA1C LEVELS IN A DIABETIC PATIENT IN ABSENCE OF DIABETIC MACULAR OEDEMA

National Journal of Medical Research, 2016
Background: This study is aimed to find out the correlation between change in macular volume on optical coherence tomography (OCT) in patients with uncontrolled HbA1c levels . Methods: It is a observational study.
Parag Apte, Priti Kumari, Debapriya Datta, Nilesh Jagdale, Jatin Patel, Richa Naik   +5 more
doaj  

Cost‐effectiveness analysis of Dexcom ONE+ real‐time continuous glucose monitoring versus self‐monitoring of blood glucose in people with type 2 diabetes in Aotearoa New Zealand

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4055-4065, May 2026.
Abstract Aims Real‐time continuous glucose monitors (rt‐CGM) have been found effective and economical for the treatment of diabetes in many countries. The objective of this study was to provide a cost‐effectiveness analysis of rt‐CGM versus self‐monitoring of blood glucose (SMBG) from the perspective of a healthcare payer in New Zealand.
Ryan G. Paul, Jessica Y. Matuoka, Hamza A. Alshannaq, Richard F. Pollock, Gregory J. Norman   +4 more
wiley   +1 more source

Impact of specialised endocrinology care on metabolic control and healthcare utilisation outcomes after kidney transplantation in patients with diabetes: A 12‐month observational cohort study

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4082-4090, May 2026.
Abstract Aims To evaluate whether an endocrinology‐integrated transplant clinic and differing healthcare delivery models are associated with metabolic outcomes during the first year after kidney transplantation in recipients with pre‐existing diabetes.
Joaquin Lado‐Abeal, Francisco Gude, Maria Jose Ginzo‐Villamayor, Khalid Al‐Zubaidi, Jacqueline C. Stocking, Gemma Rodriguez‐Carnero, Aili Guo, Prasanth Surampudi, Caroline Lenaerts, Vedesh K. Babu, Deborah Plante, Yihung Huang, Antia Fernandez‐Pombo   +12 more
wiley   +1 more source

Synergistic inhibition of macular vascular permeability in diabetic edema: Ginsenoside Rg3 enhances ranibizumab efficacy by targeting angiopoietin‐like protein 4 and vascular endothelial growth factor via neuropilin/RhoA signaling

Journal of Diabetes Investigation, Volume 17, Issue 5, Page 751-765, May 2026.
Molecular mechanism of synergistic antagonism of ANGPTL4 and VEGF by ginsenoside Rg3 combined with ranibizumab, regulating the NRP/RhoA pathway to inhibit macular edema. ABSTRACT Aims This study investigated the molecular mechanisms by which ginsenoside Rg3 combined with ranibizumab alleviates diabetic macular edema (DME), focusing on antagonizing ...
Jiexin Yu, Xingyu Li, Yanli Liu
wiley   +1 more source

Intravitreal Cidofovir Injection for Refractory End‐Stage Glaucoma and Vision Loss in Silicone Oil‐Filled Eyes Following Retinal Reattachment Surgery in Dogs: Four Cases

Veterinary Ophthalmology, Volume 29, Issue 3, May 2026.
ABSTRACT Objective To describe the clinical outcome of intravitreal cidofovir injection for palliative management of refractory end‐stage glaucoma and vision loss in silicone oil‐filled eyes following retinal reattachment surgery in dogs. Procedures Medical records of dogs that underwent a single intravitreal cidofovir injection for pharmacologic ...
Sunhyo Kim, Jaeho Shim
wiley   +1 more source

Cystoid macular oedema after trabeculectomy versus tube shunt surgery in non-diabetic patients. [PDF]

BMJ Open Ophthalmol
Elhusseiny AM, Abu Serhan H, Eleiwa TK, Ayoubi M, ElSheikh RH, Chauhan MZ, Uwaydat SH, Adelpour M, Lee RK.   +8 more
europepmc   +1 more source

Diabetic macular oedema and erythropoietin [PDF]

Eye, 2008
M Uparkar, S Kaul
openaire   +1 more source